Symtoms

FAQ

About Us

Contact

1/5

Glioblastoma multiforme, glioma grade 4 (IV) is the most common and malignant primary brain tumor. It's a type of astrocytoma. Although it can occur in children, it is more common in adults and its incidence increases with years and in the elderly. Until now, not all causes have been identified and there is no accepted global theory to explain it.

Unlike most cancers, glioblastoma only appears to develop in the brain microenvironment and does not extend to other organs or systems, being nevertheless hugely invasive and destructive. This behavior, reflected in its symptoms, along with its great intrinsic and extrinsic heterogeneity, make it one of the most difficult tumors to treat.

Despite significant advances in neurosurgical techniques, immunotherapy (vaccines), viruses, radiation therapy and different natural therapies, glioblastoma remains an incurable and high mortality disease creating individual and Social.

In recent years, patients who may receive a complete and multimodal treatment have improved survival, but the end result is not good, and the cure is difficult. Today, however, life may be easier for these survivors.

This new era conditions all the actions of the neurosurgeon to the histochemical and molecular diagnosis integrated in new protocols of action within interdisciplinary teams of the large neurosurgical centers. The IDH mutation (IDH type or wild type), or methylation of the MGMT promoter improve its classification and nanotechnology will help to move forward.

Oncologists, neurologists, radiologists, neurosurgeons and neuropathologists integrate this complex network of knowledge to be able to make the best decisions in each case. In this web you can read the latest relevant news published.

Learn about which phase III clinical trials are recruiting patients in Spain, in collaboration with other international centers and/or multicentric ways are currently being conducted in real time.

In our environment, in Spain, it is essential to adapt current knowledge to initial recommendations and  treatment explained by Dr. Marcos Escosa.